Calcium lactate veterinary grade API is supplied as the pentahydrate crystalline powder under product code CL-VP-101, with a molecular formula of C6H10CaO6·5H2O and a relative molecular mass of 308.29 g/mol. The theoretical calcium contribution is 13.0% w/w in the pentahydrate and 18.4% w/w when expressed as the anhydrous form, based on a calcium atomic mass of 40.08 g/mol. Release specifications are aligned with the Ph. Eur. monograph for calcium lactate pentahydrate and the corresponding USP monograph; typical limits are 98.0%–101.0% assay on dried basis, loss on drying 22.0%–27.0% by Ph. Eur. 2.2.32, pH 6.0–8.0 in a 5% aqueous solution by Ph. Eur. 2.2.3, chloride ≤0.005%, sulfate ≤0.075%, heavy metals ≤10 ppm by Ph. Eur. 2.4.8, arsenic ≤3 ppm by Ph. Eur. 2.4.2, and bacterial endotoxins <0.5 EU/mg by Ph. Eur. 2.6.14 when ordered for parenteral use. The material exhibits a compendial solubility of approximately 1 part in 20 parts water at 25 °C, is practically insoluble in ethanol, and produces a clear to slightly opalescent solution at 10% w/w. Elemental impurities are controlled by ICH Q3D Option 1, and residual solvents are controlled by Ph. Eur. 5.4.

What Limits Direct Compression in High-Dose Calcium Lactate Tablet Blends?

Direct compression of veterinary tablet formulations containing 55%–70% w/w calcium lactate pentahydrate is constrained primarily by particle size distribution, bulk density, and loss on drying. Production-scale batches with a d50 of 150 µm–250 µm, a fraction retained on 40 mesh of ≤10% w/w, and a Hausner ratio of 1.15–1.25 feed uniformly on rotary presses at 30–40 rpm. When d50 falls below 100 µm, hopper ratholing and die-filling variability increase; force feeder assistance is required above 30 rpm, and tablet weight variability can exceed ±5% if the hopper level is not maintained above 30% of capacity. The pentahydrate begins to lose water above 120 °C; therefore wet granulation with aqueous binders should be limited to short-contact, low-moisture methods. Dry granulation by slugging or roller compaction is preferred in high-dose formulations. Magnesium stearate at 0.5%–1.5% w/w is compatible, but mixing beyond 5 minutes reduces compact tensile strength because of crystalline surface coating. Tablet crushing strength for a 60% w/w API blend with microcrystalline cellulose and 2% croscarmellose sodium is typically 80–120 N by Ph. Eur. 2.9.8, and disintegration time is ≤15 minutes by Ph. Eur. 2.9.1.

Capsule filling with calcium lactate pentahydrate requires control of equilibrium moisture because powders above 27.0% loss on drying may clump in dosator nozzles at ambient humidity above 60% RH. For hard gelatin capsules, a formulated blend containing 45%–65% w/w API, 20%–30% lactose monohydrate, and 2%–5% crospovidone shows acceptable flow and dissolution when tested by Ph. Eur. 2.9.3; capsule fill weight variation remains within 85.0%–115.0% of label claim according to Ph. Eur. 2.9.40. Oral powders for feed or drinking water are dry-blended to a calcium dose of 100–200 mg/kg body weight per day; the material passes a 60-mesh sieve and maintains a bulk density of 0.45–0.65 g/cm³ by Ph. Eur. 2.9.34. Granular premix forms are produced with 1%–5% starch paste as binder and are dried to a loss on drying of 22.0%–25.0% to reduce caking in multi-layer paper/polyethylene sacks. For oral solutions, the API is combined with sodium benzoate 0.1% w/w and pH-adjusted to 5.5–7.0; the solution remains chemically stable for 12 months at 25 °C when protected from light.

Parenteral Solution Sterility Barriers, Endotoxin Thresholds, and Incompatibilities

Injectable solutions of calcium lactate are prepared at 10% w/w in water-for-injection; the dissolved calcium concentration is approximately 130 mg Ca²⁺/10 mL for the pentahydrate because the theoretical calcium content is 13.0% w/w. Terminal sterilisation at 121 °C for 15 minutes is feasible only when the solution pH is maintained between 5.5 and 7.0 and when phosphate, sulfate, carbonate, or bicarbonate ions are excluded; otherwise dissolved carbon dioxide loss and precipitation of calcium phosphate or calcium hydroxide produce visible particulate matter. The product is filled into Type I glass vials or polypropylene ampoules and sterilised by moist heat according to Ph. Eur. 5.1.1. Endotoxin load at release is controlled <0.5 EU/mg by Ph. Eur. 2.6.14, and the final solution must comply with Ph. Eur. 2.9.19 particulate matter limits for sub-visible particles. The lactate anion produces less parenteral acidification than chloride, but overdose can still cause hypercalcaemia; administration rates should not exceed 10 mL/min for a 10% solution in large animals. Published data for species-specific veterinary calcium lactate parenteral formulations is limited; the above parameters derive from general parenteral manufacturing practice.

Compared with calcium gluconate monohydrate, which supplies 8.9% w/w calcium, the pentahydrate form of calcium lactate delivers 13.0% w/w calcium, allowing a lower excipient load in oral boluses and a smaller dosage unit mass for equivalent elemental calcium. Compared with calcium chloride dihydrate, which contains 27.3% w/w calcium, calcium lactate is less hygroscopic and less tissue-irritating; the chloride salt is rarely used in oral tablets because of deliquescence at relative humidity above 30% RH. Calcium carbonate contains 40.0% w/w calcium but requires gastric acid for dissolution and releases carbon dioxide, which can cause bloat in ruminants; calcium lactate does not generate gas and its absorption is not acid-dependent. Calcium citrate tetrahydrate offers 21.1% w/w calcium but has poor cold-water solubility; calcium lactate dissolves more readily, making it suitable for liquid drenches, drinking-water administration, and injectable solutions. These differences are summarised in the comparative table below.

When Calcium Lactate Replaces Calcium Chloride in Hygroscopic Premixes

Replacement of calcium chloride dihydrate with calcium lactate pentahydrate in feed premixes and oral tablets becomes critical when storage relative humidity exceeds 30% RH. Calcium chloride deliquesces and forms free liquid within packaged premixes, accelerating vitamin degradation and causing metal equipment corrosion; calcium lactate pentahydrate remains a free-flowing crystalline solid at 40% RH and 25 °C when packed in polyethylene-lined paper sacks. The exchange ratio is not 1:1 because calcium chloride dihydrate contains 27.3% w/w calcium and calcium lactate pentahydrate contains 13.0% w/w calcium; a formulation requiring 100 g of calcium chloride dihydrate to supply 27.3 g of calcium requires approximately 210 g of calcium lactate pentahydrate. This substitution also shifts the chloride content of the final feed premix to zero, which may be relevant in diets requiring chloride restriction. The lower calcium loading increases total premix mass but improves flow and reduces deliquescence-related caking. Finished feed stability data should be generated on each formulation because the lactate anion may reduce local pH in high-moisture wetted feeds and accelerate Maillard reactions when reducing sugars are present.

Roller compaction of calcium lactate pentahydrate at roll pressures of 4–6 MPa and roll speeds of 3–5 min⁻¹ typically yields granules with d50 of 400–600 µm, bulk density of 0.55–0.75 g/cm³, and fines below 100 µm limited to <15% w/w. These granules dissolve more slowly than the ungranulated powder because of reduced surface area, but they improve tablet compression and allow conventional feeding without force feeder assistance. Thermal drying windows must remain below 80 °C to avoid premature loss of water of crystallisation; a drying study at 70 °C for 4 hours reduces loss on drying by only 1%–2% from the initial 22.0%–27.0% range, indicating that moderate heat can be applied during granule drying. Drying above 120 °C changes the endothermic dehydration profile and may convert the pentahydrate to anhydrous calcium lactate, altering the calcium content and the dissolution profile. The anhydrous form should not be used interchangeably with the pentahydrate in a licensed veterinary formulation without bioequivalence or stability data.

At physiological pH, calcium lactate exists almost entirely as dissociated calcium cations and lactate anions; the pKa of lactic acid at 25 °C is 3.86. This property distinguishes it from calcium carbonate, which requires gastric acid dissolution, and from calcium gluconate, which also dissolves without acid but has a larger molecular mass per calcium equivalent. In ruminant oral fluids at pH 6.0–7.0, calcium lactate remains soluble, whereas dicalcium phosphate or calcium carbonate can sediment in the rumen mat. The weak calcium–lactate association is not sufficiently strong to alter the ionised calcium concentration in blood; therefore formulation pH, not chelation, controls the risk of precipitation. For parenteral use, the osmolality of a 10% w/w solution is approximately 900–1100 mOsm/kg; dilution to isotonicity should be confirmed by Ph. Eur. 2.2.35 and adjusted with 5% dextrose or other isotonic diluents before intravenous administration.

Controlling D-Lactate Content and Crystal Habit During API Manufacture

The manufacture of calcium lactate begins with fermentation-derived lactic acid, which is neutralised with calcium hydroxide or calcium carbonate slurry, filtered, crystallised, and milled under controlled humidity. For veterinary APIs, the L-lactic acid path is preferred because the resulting L-lactate ion enters endogenous metabolic pathways; the D-lactate form is less rapidly cleared in ruminants and can accumulate if high oral doses are given over multiple days. Liquid chromatographic control of lactate enantiomers is performed by a validated chiral HPLC method in accordance with ICH Q2(R1), with a typical D-lactate limit of ≤1.0% of total lactate. The pentahydrate crystal habit is prismatic to needle-like; uncontrolled milling generates fines below 50 µm, which reduce flow and increase dusting. The residual sugar content is maintained below 0.5% and reducing substances below 0.1% to avoid Maillard browning when lactose-containing premixes are dried at 70–80 °C. Residual lactic acid and volatile fatty acids are controlled by loss on drying and by limit tests for acidity and alkalinity according to Ph. Eur. 2.2.3.

Stability studies for veterinary oral powders are conducted at 25 °C/60% RH long-term and 40 °C/75% RH accelerated storage per VICH GL3 and GL5. Batches stored in sealed aluminium/polyethylene laminates retain 98%–101% assay and loss on drying 22.0%–27.0% after 24 months; partial dehydration to the anhydrous form is not observed below 50 °C in sealed containers. Open containers at 30 °C/65% RH show no significant weight gain until 72 hours, after which minor caking develops. For injection-grade material, the endotoxin loading remains <0.5 EU/mg after 36 months when stored at 15–25 °C in sealed double polyethylene bags; sterility of the final solution is assigned by the downstream manufacturer according to Ph. Eur. 5.1.1 and is not an API release test.

The product is manufactured in closed stainless-steel process equipment under veterinary GMP conditions; batch records include in-process checks for particle size, loss on drying, and calcium content after every blending stage. At 100 kg blend scale, the relative standard deviation of calcium content in finished oral powder is below 2% when the API is pre-blended with 10% w/w colloidal silicon dioxide before main mixing. Storage in well-closed containers at 15–25 °C and ≤60% RH maintains the pentahydrate form for at least 36 months when retested at 12-month intervals. The product is not a hazardous substance under GHS classification and carries no transport restriction under 49 CFR or ADR; however, it should not be mixed with strong oxidisers or with solutions containing phosphate or sulfate ions because insoluble calcium salts will form. In multi-electrolyte oral solutions, the order of addition is: calcium lactate first, then other compatible electrolytes, with pH adjustment after complete dissolution; this prevents local supersaturation and clouding.